Briacell Therap (NASDAQ:BCTX – Get Free Report) is expected to be issuing its results before the market opens on Monday, October 27th. Analysts expect the company to announce earnings of ($12.11) per share for the quarter.
Briacell Therap Price Performance
NASDAQ BCTX opened at $13.79 on Friday. Briacell Therap has a 12 month low of $6.00 and a 12 month high of $190.50. The company has a 50-day moving average of $9.88 and a 200-day moving average of $21.98. The company has a market cap of $9.38 million, a P/E ratio of -0.17 and a beta of 1.21.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $320.00.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Recommended Stories
- Five stocks we like better than Briacell Therap
- 3 Fintech Stocks With Good 2021 Prospects
- Rayonier-PotlatchDeltic Merger Signals Industry Upside
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
- How to Use Stock Screeners to Find Stocks
- This Defense Stock Has a $57B Backlog and New AI Tailwinds
Receive News & Ratings for Briacell Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therap and related companies with MarketBeat.com's FREE daily email newsletter.
